# A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity

> **NCT07137585** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 30 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Obesity
- Overweight

## Interventions

- **DRUG:** Placebo
- **DRUG:** RO7204239

## Key facts

- **NCT ID:** NCT07137585
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2026-09-13
- **Final completion:** 2027-02-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07137585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07137585, "A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07137585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*